

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

Ms: 2554

Title: HCV-specific immune responses induced by CIGB-230 in combination with IFN- α plus ribavirin

Reviewer code: 00225256

Science editor: x.z.huang@wjgnet.com

Date sent for review: 2013-04-03 11:49

Date reviewed: 2013-04-16 14:27

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS

COMMENTS TO AUTHORS:

The manuscript titled "HCV-specific immune responses induced by CIGB-230 in combination with IFN- α plus ribavirin" is an interesting phase II clinical study evaluating the effects of triple therapy INF- α plus ribavirin and CIGB-230 in treatment naive, HCV genotype 1b infected patients and found that CIGB-230 modifies immune response in chronic patients and immune response depends on number of doses and time of administration in relation to antiviral therapy. However, I have following minor concerns which could help in overall representation of study. 1) Statistical representations and results section is too complex and difficult to understand and sentences are too long. To increase the readability and to cover the scope of the journal, I recommend to focus more on relevant positive findings rather than discussing the statistics in a complex manner. 2) After completion of therapy SVR is still not significant clinically and does not represent good therapeutic results. It should be more focused and discussed in results section. 3) Information about No. of patients who have undergone histological evaluation should be mentioned. 4) In L6 group, subgroup statistical significance was more stressed rather than discussing statistical significant of L6 group as a whole. Overall, it is a well-structured and organized study, which provides new potential option for future treatment of HCV patients.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

Ms: 2554

Title: HCV-specific immune responses induced by CIGB-230 in combination with IFN- α plus ribavirin

Reviewer code: 00225256

Science editor: x.z.huang@wjgnet.com

Date sent for review: 2013-04-03 11:49

Date reviewed: 2013-04-16 14:28

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS

COMMENTS TO AUTHORS:

The manuscript titled "HCV-specific immune responses induced by CIGB-230 in combination with IFN- α plus ribavirin" is an interesting phase II clinical study evaluating the effects of triple therapy INF- α plus ribavirin and CIGB-230 in treatment naive, HCV genotype 1b infected patients and found that CIGB-230 modifies immune response in chronic patients and immune response depends on number of doses and time of administration in relation to antiviral therapy. However, I have following minor concerns which could help in overall representation of study. 1) Statistical representations and results section is too complex and difficult to understand and sentences are too long. To increase the readability and to cover the scope of the journal, I recommend to focus more on relevant positive findings rather than discussing the statistics in a complex manner. 2) After completion of therapy SVR is still not significant clinically and does not represent good therapeutic results. It should be more focused and discussed in results section. 3) Information about No. of patients who have undergone histological evaluation should be mentioned. 4) In L6 group, subgroup statistical significance was more stressed rather than discussing statistical significant of L6 group as a whole. Overall, it is a well-structured and organized study, which provides new potential option for future treatment of HCV patients.